BMRN

Biomarin Pharmaceutical Inc

57.49

Oct 29 • 3:59 PM ET +1.49 (2.66%)

58.00

Aftermarket • 7:44 PM ET +0.51 (0.89%)

Healthcare Biotechnology USA Large NASD

Peers: ASND BBIO PTCT RARE SRPT ALNY IONS KRYS VRTX SNY

| Held by: IJH VTI VB VBK XBI VXF FBT IBB MDY DFSV

Scroll to Statements

Index	-
Market Cap	11.13B
Enterprise Value	14.47B
Income	72.97M
Sales	3.46B
Book/sh	32.66
Cash/sh	4.52
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	3221
IPO	Jul 23, 1999

P/E	155.00
Forward P/E	8.95
PEG	0.15
P/S	3.22
P/B	1.76
P/C	12.73
P/FCF	15.08
EV/EBITDA	18.26
EV/Sales	4.19
Quick Ratio	1.32
Current Ratio	2.39
Debt/Eq	0.67
LT Debt/Eq	0.56
Option/Short	Yes / Yes

EPS (ttm)	0.37
EPS next Y	6.42
EPS next Q	-0.08
EPS this Y	96.26%
EPS next Y	81.81%
EPS next 5Y	61.71%
EPS past 3/5Y	34.05% -16.79%
Sales past 3/5Y	16.55% 11.97%
EPS Y/Y TTM	-89.03%
Sales Y/Y TTM	13.69%
EPS Q/Q	-81.28%
Sales Q/Q	20.41%
Earnings	Nov 02 AMC
EPS/Sales Surpr.	26.66% 6.19%

Insider Own	1.29%
Insider Trans	-0.83%
Inst Own	102.33%
Inst Trans	1.28%
ROA	0.76%
ROE	1.18%
ROIC	0.74%
Gross Margin	73.93%
Oper. Margin	18.50%
Profit Margin	2.11%
SMA20	3.13%
SMA50	-5.44%
SMA200	-1.60%
Trades

Shs Outstand	193.54M
Shs Float	191.08M
Short Float	6.31%
Short Ratio	5.41
Short Interest	12.05M
52W High	70.98 -19.01%
52W Low	49.26 16.71%
Volatility	2.42% 2.76%
ATR (14)	1.59
RSI (14)	50.34
Beta	0.21
Rel Volume	1.18
Avg Volume	2.23M
Volume	2,618,644

Perf Week	1.52%
Perf Month	-4.18%
Perf Quarter	-4.22%
Perf Half Y	6.64%
Perf YTD	-3.26%
Perf Year	10.86%
Perf 3Y	-28.73%
Perf 5Y	-27.44%
Perf 10Y	-29.14%
Recom	1.55
Target Price	91.62
Prev Close	56.00
Price	57.49
Change %	2.66%

Consensus

Buy

Avg. Price Target

$91.62

Implied Upside

+59.4%

Analysts17incl. previous ratings

Rating Distribution11 Buy · 6 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Resumed	UUBS	Buy	$88	+53.1%
Oct 12, 2026	Upgrade	RRaymond James	Outperform → Strong Buy	$109	+89.6%
Aug 19, 2026	Initiated	BBMO Capital Markets	Outperform	$98	+70.5%
May 19, 2026	Initiated	CCitigroup	Buy	$75	+30.5%
May 11, 2026	Resumed	GGoldman	Neutral	$69	+20.0%
Apr 27, 2026	Resumed	MMorgan Stanley	Overweight	$120	+108.7%
Jan 28, 2026	Resumed	BBarclays	Overweight	$80	+39.2%
Jan 20, 2026	Upgrade	CCanaccord Genuity	Hold → Buy	$98	+70.5%
Dec 03, 2025	Downgrade	LLeerink Partners	Outperform → Market Perform	$60	+4.4%
Nov 06, 2025	Downgrade	SStifel	Buy → Hold	$61	+6.1%
Sep 08, 2025	Initiated	HH.C. Wainwright	Neutral	$60	+4.4%
Sep 03, 2025	Initiated	RRaymond James	Outperform	$85	+47.9%
Jul 03, 2025	Resumed	MMorgan Stanley	Overweight	$97	+68.7%
Feb 24, 2025	Upgrade	OOppenheimer	Perform → Outperform	$98	+70.5%
Nov 15, 2024	Initiated	WWolfe Research	Outperform	$95	+65.2%
Oct 30, 2024	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Oct 10, 2024	Resumed	RRaymond James	Outperform	$79	+37.4%
Aug 20, 2024	Upgrade	BBernstein	Mkt Perform → Outperform	$94 → $110	+91.3%
May 17, 2024	Downgrade	RRobert W. Baird	Outperform → Neutral	$104 → $72	+25.2%
May 14, 2024	Initiated	EEvercore ISI	Outperform	$113	+96.6%

Oct-26-26 11:54AM	BioMarin Must Prove Voxzogo Can Hold Ground As Amicus Lifts Revenue Toward $1 Billion (Earnings Whispers)
09:00AM	BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET (PR Newswire)
Oct-09-26 11:36AM	Is Vertex Stock Worth More Than Its Competitors? (Trefis)
09:05AM	BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting (PR Newswire)
Oct-05-26 04:05PM	BioMarin Appoints Cara Bauer as Chief People Officer (PR Newswire)
11:00AM	Loading…
Oct-02-26 11:00AM	BioMarin Announces Five-Year Phase 3 Data for POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at World Muscle Society Annual Congress (PR Newswire)
Oct-01-26 05:36AM	BioMarin and Profluent partner on AI-designed enzyme therapies (Pharmaceutical Technology)
Sep-14-26 09:05AM	BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (PR Newswire)
Sep-11-26 01:00AM	Growth Without AI: 8 Stock Picks (Barrons.com)
Sep-09-26 09:05AM	BioMarin Announces Positive Results of Phase 3 VOXZOGO (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence (PR Newswire)
Sep-04-26 03:24AM	RARE Stock Crashes In Worst Day Ever Pharma Bro Martin Shkreli Calls It Very Cheap, Floats BioMarin Buyout (Stocktwits)
Sep-02-26 09:00AM	BioMarin to Participate in Upcoming Investor Conferences (PR Newswire)
06:12AM	Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute (BioPharma Dive)
Sep-01-26 09:05AM	BioMarin Announces Close of the Alesta Therapeutics Acquisition (PR Newswire)
Aug-31-26 01:30PM	ASND, BMRN Stocks Rise: Street Calls Patent Peace A Clean Overhang Lift, Keep Ratings Unchanged (Stocktwits)
02:00AM	Loading…
02:00AM	BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea (PR Newswire)
Aug-19-26 01:24PM	BioMarin acquiring Alesta Therapeutics for $275 million (Quartz)
10:55AM	BioMarin spends up to $490m for Alestas bone disease candidate (Pharmaceutical Technology)
Aug-18-26 01:36PM	BMRN Stock Rises On Up To $490M Alesta Deal, But Analyst Cuts Price Target To $59 Heres Why (Stocktwits)
09:41AM	BioMarin Shares Jump After $275 Million Deal to Acquire Alesta Therapeutics (InvestorsHub)
08:30AM	BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline (PR Newswire)
07:50AM	BioMarin acquires experimental drug for rare bone disorder in $275M deal (BioPharma Dive)
Aug-12-26 05:11AM	Silence cashes in on differentiated data; UK reaffirms support for childhood vaccines (BioPharma Dive)
Aug-10-26 09:05AM	BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston (PR Newswire) +7.95%
Aug-07-26 01:11AM	BioMarin Pharmaceutical Inc (BMRN) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
Aug-06-26 04:23PM	BioMarin: Q2 Earnings Snapshot (Associated Press)
04:03PM	BioMarin Reports Second Quarter 2026 Financial and Operating Results (PR Newswire)
Jul-30-26 09:00AM	BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET (PR Newswire)
Jul-28-26 06:30AM	BioMarin and n-Lorem partner on early research for ReNU syndrome therapy (Pharmaceutical Technology)
Jul-27-26 09:05AM	BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome (PR Newswire)
09:06AM	Loading…
Jul-16-26 09:06AM	Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jul-13-26 09:05AM	U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia (PR Newswire)
Jul-10-26 08:14AM	Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act? (Trefis)
Jul-08-26 08:48AM	Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside (Trefis)
Jun-16-26 09:05AM	BioMarin Announces New Three-Year VOXZOGO (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 (PR Newswire)
Jun-02-26 01:30AM	Centene, Deckers and 14 Other 'Dividend Hopefuls' (Barrons.com)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com) +8.63%
May-20-26 04:20PM	BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO (vosoritide) in Children with Hypochondroplasia (PR Newswire) +7.77%
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
07:58AM	BioMarin drug acquired in buyout misses goal in rare disease study (BioPharma Dive)
May-18-26 09:05AM	BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency (PR Newswire)
May-11-26 09:44AM	Dell downgraded, Uber upgraded: Wall Street's top analyst calls (The Fly)
May-04-26 04:25PM	BioMarin: Q1 Earnings Snapshot (Associated Press)
04:05PM	BioMarin Reports First Quarter 2026 Financial and Operating Results (PR Newswire)
May-02-26 03:30PM	BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting (PR Newswire)
Apr-28-26 05:51AM	BioMarin acquires Amicus Therapeutics for $4.8bn (Pharmaceutical Technology)
Apr-27-26 09:51AM	Snap upgraded, Pinterest downgrade: Wall Street's top analyst calls (The Fly)
08:44AM	BioMarin Completes Acquisition of Amicus Therapeutics (PR Newswire)
07:30AM	BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET (PR Newswire)
Apr-21-26 04:23PM	BioMarin Announces Board Leadership Transition (PR Newswire)
Mar-12-26 09:05AM	BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting (PR Newswire)
Mar-10-26 02:49PM	BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz (Benzinga)
Mar-09-26 02:45PM	Do Options Traders Know Something About BMRN Stock We Don't? (Zacks)
Mar-07-26 02:48AM	BioMarin Pharmaceutical Details Strategy Refresh, Voxzogo Competition and 40% Margin Goal at TD Cowen Confab (MarketBeat)
Mar-04-26 06:00AM	BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients (Benzinga)
Mar-02-26 11:04PM	2 Reasons to Like BMRN (and 1 Not So Much) (StockStory)
07:22AM	Ascendis wins FDA approval of dwarfism drug (BioPharma Dive)
06:10AM	BioMarin Strengthens PKU Portfolio With FDA Approval For Younger Patients (Benzinga)
Mar-01-26 04:27AM	Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 - Here's Why (Insider Monkey)
Feb-28-26 02:21AM	Bernstein Lifts PT on BioMarin Pharmaceutical (BMRN) to $94 From $90, Here's Why (Insider Monkey)
Feb-27-26 08:00PM	U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU) (PR Newswire)
Feb-26-26 12:36PM	BioMarin Pharmaceutical Inc. (BMRN) Seen as Attractive Buy Ahead of Transcon-CNP PDUFA, Says Wells Fargo (Insider Monkey)
04:39AM	Boehringer drug approved in 44 days; BioMarin shelves Roctavian (BioPharma Dive)
Feb-24-26 04:51PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
11:35AM	BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market (Zacks)
09:50AM	Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock (Zacks)
09:00AM	BioMarin to Participate in Four Upcoming Investor Conferences in March (PR Newswire)
12:02AM	BioMarin Pharmaceutical Inc (BMRN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-23-26 08:00PM	Compared to Estimates, BioMarin (BMRN) Q4 Earnings: A Look at Key Metrics (Zacks)
07:25PM	BioMarin Pharmaceutical (BMRN) Beats Q4 Earnings and Revenue Estimates (Zacks)
06:18PM	BioMarin Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
05:08PM	BioMarin: Q4 Earnings Snapshot (Associated Press Finance)
04:50PM	BioMarin Pharmaceutical's (NASDAQ:BMRN) Q4 CY2025 Sales Beat Estimates (StockStory)
04:05PM	BioMarin Reports Fourth Quarter and Full-year 2025 Financial and Operating Results (PR Newswire)
11:12AM	Amicus' Q4 Earnings Miss, Higher Product Sales Drive Y/Y Revenues (Zacks)
Feb-21-26 10:07PM	BioMarin Pharmaceutical Earnings: What To Look For From BMRN (StockStory)
Feb-19-26 09:15AM	Countdown to BioMarin (BMRN) Q4 Earnings: Wall Street Forecasts for Key Metrics (Zacks)
Feb-17-26 09:00AM	BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET (PR Newswire)
Feb-16-26 02:11PM	What to Expect From These Drug/Biotech Players This Earnings Season? (Zacks)
12:24PM	What Makes BioMarin (BMRN) so Attractive (Insider Monkey)
Feb-13-26 04:31PM	Analyst Report: BioMarin Pharmaceutical Inc. (Morningstar Research)
Feb-12-26 04:05PM	BioMarin Announces Closing of Private Offering of Senior Notes (PR Newswire)
12:44PM	BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 (Benzinga)
10:00AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
08:30AM	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
Feb-08-26 03:49AM	What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? (Insider Monkey)
Feb-07-26 04:09AM	Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays (Insider Monkey)
Jan-31-26 05:04AM	Should You Buy BioMarin Pharmaceutical Before Feb. 18? (Motley Fool)
Jan-29-26 04:05PM	BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
06:57AM	Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) (Insider Monkey)
Jan-27-26 07:22AM	Double-digit Revenue Growth Till 2030 Drives BioMarin's (BMRN) Bullish Thesis (Insider Monkey)
Jan-26-26 07:45AM	BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility (PR Newswire)
Jan-22-26 06:02AM	BioMarin vets form Mendra to modernize rare disease drug development (BioPharma Dive)
Jan-16-26 11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:50AM	Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-26 10:08AM	Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical (Zacks)
08:47AM	Buy These 5 Price-to-Book Value Stocks for Gains in 2026 (Zacks)
Jan-14-26 12:25PM	Humana Partners With Atlas to Enhance Cancer Care for Seniors (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Davis George Eric	EVP, Chief Legal Officer	Sep 02 '26	Sale	66.28	17,557	1,163,748	61,003	Sep 03 06:41 PM
Davis George Eric	Officer	Sep 02 '26	Proposed Sale	66.28	17,557	1,163,756		Sep 02 02:55 PM
Friberg Gregory R	EVP, Chief R&D Officer	May 07 '26	Sale	53.85	3,281	176,682	51,818	May 11 05:01 PM
Friberg Gregory R	Officer	May 07 '26	Proposed Sale	53.85	3,281	176,682		May 07 01:17 PM
Guyer Charles Greg	EVP, Chief Technical Officer	Mar 11 '26	Sale	60.46	16,486	996,744	79,953	Mar 12 07:55 PM
Guyer Charles Greg	Officer	Mar 11 '26	Proposed Sale	60.46	16,486	996,749		Mar 11 03:23 PM
Friberg Gregory R	EVP, Chief R&D Officer	Feb 26 '26	Sale	60.38	6,326	381,937	37,578	Feb 26 08:39 PM
Davis George Eric	EVP, Chief Legal Officer	Feb 26 '26	Sale	61.36	26,061	1,599,103	72,453	Feb 26 08:31 PM
Friberg Gregory R	Officer	Feb 26 '26	Proposed Sale	60.38	6,326	381,937		Feb 26 01:59 PM
Davis George Eric	Officer	Feb 26 '26	Proposed Sale	61.36	26,061	1,599,103		Feb 26 10:18 AM

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

PresidentMr. Alexander Hardy

CFO & Executive VP of FinanceMr. Brian R. Mueller CPA

Executive VP & CTODr. C. Greg Guyer Ph.D.

Executive VP & Chief Commercial OfficerMs. Cristin Hubbard

Executive VP and Chief Research & Development OfficerDr. Gregory Friberg M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BMRN

Biomarin Pharmaceutical Inc

Upgrade your Finviz experience